RESEARCH PAPER
A study on local therapy technique that can be used in treatment of AIDS and some other diseases
1
Gizan General Hospital, KSA, Saudi Arabia
Submission date: 2019-03-08
Final revision date: 2019-05-06
Acceptance date: 2019-05-07
Publication date: 2019-06-17
HIV & AIDS Review 2019;18(3):193-198
KEYWORDS
TOPICS
epidemiology - population studiespsychological aspects of HIV and AIDSsocio-medical aspects of HIV and AIDSeducational aspects of HIV and AIDSpatient-physician relationship
ABSTRACT
Introduction:
Local therapy is treatment that is directed to a specific organ or limited area of the body. It can shorten the length of infection, reduce complications, and reduce the spread to other tissues or organs. In some cases, it may be more effective, more specific and better than systematic therapy, with fewer side effects. In this research, I tried to evaluate and develop the use and implementation of some of these local therapy medications in treatment of some diseases including acquired immunodeficiency syndrome (AIDS).
Material and methods:
I used in this research direct face-to-face questionnaires to get my answers and data from adult people who experienced these diseases and therapies before. They provided me with all required information without identification data and without the need of any consent or legal permissions. Also I collected retrospectively registered data as nominal data to be easier in calculation and evaluation with a probability value p < 0.05.
Results:
I got some data and results with a significant difference, e.g. 103 (103 from 129 total sample = 79.84%) patients with minor superficial wounds, who have an experience with these diseases and both of local and systematic therapies before, said that they had a faster recovery (by 2-3 days) if using a combination of a systematic antibiotic with a local antibiotic cream than using the same systematic antibiotic alone. Also, 4 patients (from a total sample of 6 = 66.66%) with AIDS got a faster and better outcome in decreasing viral load if using a combination of systematic oral antiretroviral treatment with injectable intramuscular injection of antiretroviral treatment (oral zidovudine 300 mg + lamivudine 150 mg USP, one tablet once daily for 24 weeks and with injection (intramuscular dosing) antiretroviral therapy, as injectable cabotegravir 400 mg + rilpivirine 600 mg one vial dose every 4 weeks for 24 weeks).
Conclusions:
The study revealed that we can use and develop some medications as an effective therapy in treatment of some diseases, including human immunodeficiency virus. I have suggested in this research a new additional way for treatment of AIDS, taking into account the possible side effects.
Local therapy is treatment that is directed to a specific organ or limited area of the body. It can shorten the length of infection, reduce complications, and reduce the spread to other tissues or organs. In some cases, it may be more effective, more specific and better than systematic therapy, with fewer side effects. In this research, I tried to evaluate and develop the use and implementation of some of these local therapy medications in treatment of some diseases including acquired immunodeficiency syndrome (AIDS).
Material and methods:
I used in this research direct face-to-face questionnaires to get my answers and data from adult people who experienced these diseases and therapies before. They provided me with all required information without identification data and without the need of any consent or legal permissions. Also I collected retrospectively registered data as nominal data to be easier in calculation and evaluation with a probability value p < 0.05.
Results:
I got some data and results with a significant difference, e.g. 103 (103 from 129 total sample = 79.84%) patients with minor superficial wounds, who have an experience with these diseases and both of local and systematic therapies before, said that they had a faster recovery (by 2-3 days) if using a combination of a systematic antibiotic with a local antibiotic cream than using the same systematic antibiotic alone. Also, 4 patients (from a total sample of 6 = 66.66%) with AIDS got a faster and better outcome in decreasing viral load if using a combination of systematic oral antiretroviral treatment with injectable intramuscular injection of antiretroviral treatment (oral zidovudine 300 mg + lamivudine 150 mg USP, one tablet once daily for 24 weeks and with injection (intramuscular dosing) antiretroviral therapy, as injectable cabotegravir 400 mg + rilpivirine 600 mg one vial dose every 4 weeks for 24 weeks).
Conclusions:
The study revealed that we can use and develop some medications as an effective therapy in treatment of some diseases, including human immunodeficiency virus. I have suggested in this research a new additional way for treatment of AIDS, taking into account the possible side effects.
REFERENCES (27)
1.
National Cancer Institute. Available at: https://www.cancer.gov/publica... (Accessed: 18.01.2019).
2.
Perelson AS, Neumann AU, Markowitz M, et al. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996; 271: 1582-1586.
4.
Kiguba MN. Discontinuation and modification of highly active antiretroviral therapy in HIV-infected Ugandans: prevalence and associated factors. J Acquir Immune Defic Syndr 2007; 45: 218-223.
5.
Antiretroviral Therapy for Human Immunodeficiency Virus Infection. Mandell Douglas and Bennett’s Principles and Practice of Infectious Diseases. 7th ed. Churchill Livingstone, 2009.
6.
Price RW. The two faces of HIV infection of cerebrospinal fluid. Trends Microbiol 2000; 8: 387-391.
7.
Wang L, Mondal D, La Russa VF, et al. Suppression of clonogenic potential of human bone marrow mesenchymal stem cells by HIV type 1, putative role of HIV-1 tat protein and inflammatory cytokines. AIDS Res Hum Retroviruses 2002; 18: 917-931.
8.
Edén A, Fuchs D, Hagberg L, et al. HIV-1 viral escape in cerebrospinal fluids of subjects on suppressive antiretroviral treatment. J Infect Dis 2010; 202: 1819-1825.
9.
Clifford DB. Viral escape in cerebrospinal fluid – an Achilles heel of HIV therapy? J Infect Dis 2010; 202: 1768-1769.
10.
Brace I. Questionnaire design: How to Plan, Structure and Write Survey Material for Effective Market Research. Kogan Page Publis-hers, 2008.
11.
Biros M. Research without consent: Current status, 2003. Ann Emerg Med 2003; 42: 550-564.
12.
Biros M. Research without consent: Exception from and waiver of informed consent in resuscitation research. Sci Eng Ethics 2007; 13: 361-369.
13.
Weinger MB, Slagle J, Jain S, et al. Retrospective data collection and analytical techniques for patient safety studies. Journal of Biomedical Informatics 2003; 36: 106-119.
14.
Weiss DJ. Nominal analysis of “variable”. Behavior Research Methods 2009; 41: 901-908.
15.
Johnson VE. Revised standards for statistical evidence, Proc Natl Acad Sci U S A 2013; 110: 19131-19317.
16.
Bolstad WM, Curran JM. Introduction to Bayesian statistics. 3rd ed. John Wiley & Sons, Hoboken 2017.
17.
Sarkies MN, Bowles KA, Skinner EH, et al. Data Collection Methods in Health Services Research. Hospital Length of Stay and Discharge Destination. Appl Clin Inform 2015; 6: 96-109.
18.
Mobula L, Barnhart M, Malati C, et al. Long-acting, injectable anti¬retroviral therapy for the management of HIV infection: an update on a potential game-changer. J AIDS Clin Res 2015; 6: 1-5.
19.
Scientific Committee on AIDS. Recommended principles of antiretroviral therapy in HIV disease, 2005. Available at: http://www.aids.gov.hk (Accessed: 26.06.2006).
20.
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. US Department of Health and Human Services, 2015.
21.
Margolis DA, Gonzales-Garcia J, Stellbrink HJ. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomized, open-label, phase 2b, non-inferiority trial. Lancet 2017; 390: 1499-1510.
22.
Bartlett JA, Shao JF. Successes, challenges, and limitations of current antiretroviral therapy in low-income and middle-income countries. Lancet Infect Dis 2009; 9: 637-649.
23.
Woldmedhin B, Wabe NT. The reason for Regimen change among HIV/IDS patients initiated on first line highly active antiretroviral therapy in southern Ethiopia. N Am J Med Sci 2012; 4: 19-23.
25.
FDA-Approved HIV Medicines. Available at: https://aidsinfo.nih.gov/under...- medicines (Accessed: 25.02.2019).
26.
Prentice RL. A case-cohort design for epidemiologic cohort studies and disease prevention trials. Biometrika 1986; 73: 1-11.
27.
Shy CM. Epidemiology 160/600. Introduction to Epidemiology for Public Health course lectures, 1994-2001. Department of Epidemiology, The University of North Carolina at Chapel Hill.
Share
RELATED ARTICLE
| eISSN: | 1732-2707 |
| ISSN: | 1730-1270 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
